Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
St Clair, E William
Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. [electronic resource] - Arthritis and rheumatism Apr 2013 - 1097-106 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1529-0131
10.1002/art.37850 doi
Adult
Aged
Antibodies, Monoclonal, Murine-Derived--adverse effects
Autoantibodies--blood
B-Lymphocytes--cytology
Female
Flow Cytometry
Humans
Immunologic Factors--adverse effects
Lymphocyte Count
Middle Aged
Prospective Studies
Rituximab
Sjogren's Syndrome--blood
Treatment Outcome
Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. [electronic resource] - Arthritis and rheumatism Apr 2013 - 1097-106 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1529-0131
10.1002/art.37850 doi
Adult
Aged
Antibodies, Monoclonal, Murine-Derived--adverse effects
Autoantibodies--blood
B-Lymphocytes--cytology
Female
Flow Cytometry
Humans
Immunologic Factors--adverse effects
Lymphocyte Count
Middle Aged
Prospective Studies
Rituximab
Sjogren's Syndrome--blood
Treatment Outcome